Shares in Ultracharge surge on back of Epsilor licensing agreement
Shares in battery technology group, UltraCharge (ASX: UTR) have traded strongly in August, increasing 30% from 2.3 cents at the end of July to hit an intraday high of 3 cents on Wednesday.
Of course, it should be noted that share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.
This appeared to be partly driven by positive developments announced in the company’s quarterly report which was released on July 28. However, news released on Thursday morning in relation to an exclusive license agreement for new battery intellectual property triggered another surge.
Before discussing this most recent development, it is important to understand UTR’s current position. The company is based in Israel and has acquired exclusive rights to patented technology from the Nanyang Technology University in Singapore (NTU).
The technology will replace graphite in anodes (negative pole) with a nanotube gel material made from titanium dioxide, in lithium batteries. This technology has the potential to revolutionise the market for lithium batteries by producing a battery that is not only safe with a fast charging period, but also offers a longer lifetime.
Having established a laboratory facility in Israel to conduct nanotube synthesis and fabrication of the nanotube anode, UTR is discussing supply options with end users in the global battery market.
Acquisition of license agreement boosts research capacity
The licensing agreement announced today between UTR and Epsilor Electric Fuel provides UTR with an exclusive license option for new battery intellectual property, and the company has also entered into an agreement with the group for the lease of its research facilities and the hire of specialised equipment, allowing it to expand its research team with additional resources.
By way of background, Epsilor is a subsidiary of Arotech Corporation’s (NASDAQ: ARTX) power sources division, which consists of the Epsilor-electric fuel facilities in Israel and UEC in South Carolina.
As part of the agreement, UTR will have the opportunity to expand its intellectual property portfolio with the option to purchase 100% of all rights and title in Epsilor’s intellectual property.
This will provide further assistance in the company pursuing its goal of efficiently producing nanotube material and increasing the density capacity of the materials which determine battery size.
In commenting on the license agreement, UTR’s Chief Executive Kobe Ben-Shabat said, “This exclusive license agreement over Epsilor’s intellectual property is an exciting opportunity for UTR to diversify its product offerings in energy storage solutions, as well as allowing us to expand our resources in terms of facilities, equipment and expertise which will enable us to fast track delivery of our current research programs in developing a world-class lithium battery using nanofiber materials.”
In collaboration with Leclanche, UTR will conduct a pilot project to test and evaluate its technology with a view to developing a cost competitive and large-scale manufacture of a high-cycling, fast charging and high energy density battery aimed at the Electric Vehicle market.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.